Ionis appoints Michael Yang to Board of Directors, expanding board to 10

IONIS PHARMACEUTICALS INC

Michael Yang appointed to Ionis board effective December 14, 2023.
Yang most recently served as CEO of ViaCyte, acquired by Vertex in 2022.
Former EVP & Chief Commercial Officer at Acadia Pharmaceuticals (2017-2021).
Yang previously President of Janssen Biotech, generating over $8B in annual revenues.
Will receive standard non-employee director cash and equity compensation.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Michael Yang

Director

IONS · IONIS PHARMACEUTICALS INC

Effective: 2023-12-14
Filed: December 14, 2023, 6:59 PM ET

On December 14, 2023, the Board of Directors (“ Board ”) of Ionis Pharmaceuticals, Inc. (the “ Company ”) appointed Michael Yang as a member of the Company’s Board effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Michael Yang was appointed as Director at IONIS PHARMACEUTICALS INC.

Action: appointed
Role: Director

Exact text from the filing

On December 14, 2023, the Board of Directors (“ Board ”) of Ionis Pharmaceuticals, Inc. (the “ Company ”) appointed Michael Yang as a member of the Company’s Board effective immediately.

View on SEC.gov

IONIS PHARMACEUTICALS INC filing history →

Source: SEC EDGAR

accession 0001140361-23-057644

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.